You are here

trastuzumab deruxtecan

Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study

Endpoints

Mon, 01/27/20 - 10:44 am

trastuzumab deruxtecan

Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals

BioPharma Dive

Fri, 12/20/19 - 08:19 pm

trastuzumab deruxtecan

SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance

EP Vantage

Wed, 12/11/19 - 10:24 am

trastuzumab deruxtecan

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Pharmaforum

Wed, 11/6/19 - 10:18 am

Seattle Genetics

trastuzumab deruxtecan

AstraZeneca gets Q2 2020 PDUFA date for breast cancer ADC

Fierce Biotech

Thu, 10/17/19 - 10:48 am

antibody-drug conjugate

trastuzumab deruxtecan

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Motley Fool

Wed, 06/12/19 - 09:45 am

Vertex Pharmaceuticals

tezacaftor/ivacaftor

trastuzumab deruxtecan

AstraZeneca's share dilution gamble on Daiichi drug pays off

Biopharma Dive

Thu, 05/9/19 - 10:49 am

trastuzumab deruxtecan

metastatic breast cancer

AZ and Daiichi to file new breast cancer drug after trial success

Pharmaforum

Wed, 05/8/19 - 10:05 am

trastuzumab deruxtecan

antibody-drug conjugate

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

Yahoo/Reuters

Fri, 03/29/19 - 10:06 am

trastuzumab deruxtecan